PTCT Quote, Financials, Valuation and Earnings

Rocket Pharmaceuticals has a net margin of 73.68% compared to PTC Therapeutics's net margin of --. PTC Therapeutics's return on equity of -- beat Rocket Pharmaceuticals's return on equity of --.

PTC Therapeutics has a consensus price target of $61.13, signalling upside risk potential of 30.77%. On the other hand Rocket Pharmaceuticals has an analysts' consensus of $35.75 which suggests that it could grow by 490.42%. Given that Rocket Pharmaceuticals has higher upside potential than PTC Therapeutics, analysts believe Rocket Pharmaceuticals is more attractive than PTC Therapeutics.

PTC Therapeutics has a beta of 0.522, which suggesting that the stock is 47.837% less volatile than S&P 500. In comparison Rocket Pharmaceuticals has a beta of 1.023, suggesting its more volatile than the S&P 500 by 2.26%.

PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rocket Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. Rocket Pharmaceuticals pays out -- of its earnings as a dividend.

PTC Therapeutics quarterly revenues are $1.2B, which are larger than Rocket Pharmaceuticals quarterly revenues of --. PTC Therapeutics's net income of $866.6M is higher than Rocket Pharmaceuticals's net income of -$61.3M. Notably, PTC Therapeutics's price-to-earnings ratio is 7.18x while Rocket Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 2.09x versus -- for Rocket Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 73.68% compared to PTC Therapeutics's net margin of 26.7%. PTC Therapeutics's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.7%.

PTC Therapeutics has a consensus price target of $61.13, signalling upside risk potential of 30.77%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $797.21 which suggests that it could grow by 39.53%. Given that Regeneron Pharmaceuticals has higher upside potential than PTC Therapeutics, analysts believe Regeneron Pharmaceuticals is more attractive than PTC Therapeutics.

PTC Therapeutics has a beta of 0.522, which suggesting that the stock is 47.837% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.15% to investors and pays a quarterly dividend of $0.88 per share. PTC Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

PTC Therapeutics quarterly revenues are $1.2B, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. PTC Therapeutics's net income of $866.6M is higher than Regeneron Pharmaceuticals's net income of $808.7M. Notably, PTC Therapeutics's price-to-earnings ratio is 7.18x while Regeneron Pharmaceuticals's PE ratio is 14.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 2.09x versus 4.63x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 73.68% compared to PTC Therapeutics's net margin of -60.08%. PTC Therapeutics's return on equity of -- beat Sarepta Therapeutics's return on equity of -20.94%.

PTC Therapeutics has a consensus price target of $61.13, signalling upside risk potential of 30.77%. On the other hand Sarepta Therapeutics has an analysts' consensus of $94.52 which suggests that it could grow by 164.46%. Given that Sarepta Therapeutics has higher upside potential than PTC Therapeutics, analysts believe Sarepta Therapeutics is more attractive than PTC Therapeutics.

PTC Therapeutics has a beta of 0.522, which suggesting that the stock is 47.837% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.846, suggesting its less volatile than the S&P 500 by 15.365%.

PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

PTC Therapeutics quarterly revenues are $1.2B, which are larger than Sarepta Therapeutics quarterly revenues of $744.9M. PTC Therapeutics's net income of $866.6M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, PTC Therapeutics's price-to-earnings ratio is 7.18x while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 2.09x versus 1.78x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 73.68% compared to PTC Therapeutics's net margin of 23.33%. PTC Therapeutics's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -6.04%.

PTC Therapeutics has a consensus price target of $61.13, signalling upside risk potential of 30.77%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.30 which suggests that it could grow by 15.81%. Given that PTC Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe PTC Therapeutics is more attractive than Vertex Pharmaceuticals.

PTC Therapeutics has a beta of 0.522, which suggesting that the stock is 47.837% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.511, suggesting its less volatile than the S&P 500 by 48.928%.

PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

PTC Therapeutics quarterly revenues are $1.2B, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. PTC Therapeutics's net income of $866.6M is higher than Vertex Pharmaceuticals's net income of $646.3M. Notably, PTC Therapeutics's price-to-earnings ratio is 7.18x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 2.09x versus 10.08x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.